X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through agreement, Neuraxpharm will focus on the commercialization of Briumvi (ublituximab) in Europe, for the treatment of adults patients with relapsing forms of multiple sclerosis.
Lead Product(s): Ublituximab
Therapeutic Area: Neurology Product Name: Briumvi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Neuraxpharm
Deal Size: $645.0 million Upfront Cash: $152.5 million
Deal Type: Agreement February 26, 2024
Details:
Under the agreement, TG Therapeutics received exclusive worldwide rights to develop and commercialize Precision’s Azercabtagene Zapreleucel (azer-cel), an allogeneic CD19 CAR T cell therapy program for autoimmune diseases and all other non-oncology indications.
Lead Product(s): Azercabtagene Zapreleucel
Therapeutic Area: Immunology Product Name: Azer-cel
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Precision BioSciences
Deal Size: $305.5 million Upfront Cash: $17.5 million
Deal Type: Licensing Agreement February 12, 2024
Details:
Under the agreement, TG Therapeutics will receive exclusive worldwide rights to develop and commercialize Precision’s Azercabtagene Zapreleucel (azer-cel), an allogeneic CD19 CAR T cell therapy program for autoimmune diseases and all other non-oncology indications.
Lead Product(s): Azercabtagene Zapreleucel
Therapeutic Area: Immunology Product Name: Azer-cel
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Precision BioSciences
Deal Size: $315.5 million Upfront Cash: $7.5 million
Deal Type: Licensing Agreement January 09, 2024
Details:
Under the agreement, TG Therapeutics will commercialise Briumvi (ublituximab), the first and only anti-CD20 monoclonal antibody approved in the United States and European Union for adult patients with relapsing forms of multiple sclerosis.
Lead Product(s): Ublituximab-xiiy
Therapeutic Area: Neurology Product Name: Briumvi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Neuraxpharm
Deal Size: $645.0 million Upfront Cash: $140.0 million
Deal Type: Licensing Agreement August 01, 2023
Details:
Briumvi (Ublituximab-xiiy) is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of autoimmune disorders, such as RMS.
Lead Product(s): Ublituximab-xiiy
Therapeutic Area: Neurology Product Name: Briumvi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
Briumvi (Ublituximab-xiiy) is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of autoimmune disorders, such as RMS.
Lead Product(s): Ublituximab-xiiy
Therapeutic Area: Neurology Product Name: Briumvi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2023
Details:
Briumvi (Ublituximab-xiiy) is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of autoimmune disorders, such as RMS.
Lead Product(s): Ublituximab-xiiy
Therapeutic Area: Neurology Product Name: Briumvi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
Briumvi (Ublituximab-xiiy) is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of autoimmune disorders, such as RMS.
Lead Product(s): Ublituximab-xiiy
Therapeutic Area: Neurology Product Name: Briumvi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2023
Details:
BRIUMVI (ublituximab-xiiy), is the first and only anti-CD20 monoclonal antibody approved for patients with RMS that can be administered in a one-hour infusion following the starting dose.
Lead Product(s): Ublituximab-xiiy
Therapeutic Area: Neurology Product Name: Briumvi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 28, 2022
Details:
TG-1101 (ublituximab) is an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, binds to the B-cell it triggers a series of immunological reactions.
Lead Product(s): Ublituximab
Therapeutic Area: Neurology Product Name: TG-1101
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
